Spots Global Cancer Trial Database for Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Official Title: A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors

Study ID: NCT01859351

Conditions

Advanced Solid Tumours

Interventions

WX-037

WX-554

Study Description

Brief Summary: The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.

Detailed Description: